📊 QNCX Key Takeaways
Is Quince Therapeutics, Inc. (QNCX) a Good Investment?
Quince Therapeutics is a pre-revenue biotech company burning $7.6M annually in operating cash flow with only ~2.4 years of cash runway remaining. The $35.9M net income appears driven by non-operating gains rather than core business operations, as evidenced by negative $14.6M operating income, creating a fundamental disconnect between reported earnings and operational reality.
Quince Therapeutics, Inc. Key Strengths (QNCX)
- Strong balance sheet with $18.2M cash against $26.6M total assets
- Zero long-term debt eliminates refinancing and solvency risk
- Solid liquidity metrics with 2.92x current ratio
QNCX Stock Risks: Quince Therapeutics, Inc. Investment Risks
- No revenue generation despite matured company status indicates failed commercialization or prolonged development stage
- Negative $7.6M annual operating cash burn with only 2-3 years of cash runway before capital requirements
- Operating income of -$14.6M versus net income of +$35.9M indicates non-operating gains masking operational losses and deteriorating EPS trends
- Zero insider Form 4 activity suggests lack of management confidence in fundamental business trajectory
Key Metrics to Watch
- Operating cash flow trend and projected runway before capital raise needed
- Revenue recognition timing and pipeline advancement status
- Cash burn rate relative to available liquidity
- Nature and sustainability of non-operating gains driving net income
Quince Therapeutics, Inc. (QNCX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.92x current ratio provides a solid financial cushion.
QNCX Profit Margin, ROE & Profitability Analysis
QNCX vs Healthcare Sector: How Quince Therapeutics, Inc. Compares
How Quince Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Quince Therapeutics, Inc. Stock Overvalued? QNCX Valuation Analysis 2026
Based on fundamental analysis, Quince Therapeutics, Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Quince Therapeutics, Inc. Balance Sheet: QNCX Debt, Cash & Liquidity
QNCX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Quince Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.31 indicates the company is currently unprofitable.
QNCX Revenue Growth, EPS Growth & YoY Performance
Quince Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
QNCX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Quince Therapeutics, Inc. (CIK: 0001662774)
📋 Recent SEC Filings
❓ Frequently Asked Questions about QNCX
What is the AI rating for QNCX?
Quince Therapeutics, Inc. (QNCX) has an AI grade of C with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are QNCX's key strengths?
Claude: Strong balance sheet with $18.2M cash against $26.6M total assets. Zero long-term debt eliminates refinancing and solvency risk.
What are the risks of investing in QNCX?
Claude: No revenue generation despite matured company status indicates failed commercialization or prolonged development stage. Negative $7.6M annual operating cash burn with only 2-3 years of cash runway before capital requirements.
What is QNCX's revenue and growth?
Quince Therapeutics, Inc. reported revenue of N/A.
Does QNCX pay dividends?
Quince Therapeutics, Inc. does not currently pay dividends.
Where can I find QNCX SEC filings?
Official SEC filings for Quince Therapeutics, Inc. (CIK: 0001662774) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is QNCX's EPS?
Quince Therapeutics, Inc. has a diluted EPS of $2.88.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is QNCX's fundamental grade?
Based on our AI fundamental analysis in May 2026, Quince Therapeutics, Inc. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is QNCX stock overvalued or undervalued?
Valuation metrics for QNCX: ROE of 229.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
What is QNCX's AI grade for 2026?
Our dual AI analysis gives Quince Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is QNCX's free cash flow?
Quince Therapeutics, Inc.'s operating cash flow is $-7.6M, with capital expenditures of $0.0.
How does QNCX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE 229.1% (avg: 15%), current ratio 2.92 (avg: 2).
Why is QNCX's return on equity (ROE) so high?
Quince Therapeutics, Inc. has a return on equity of 229.1%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity.